The US Patent and Trademark Office issued Corning Incorporated an additional patent related to the Corning Epic System that deals with the study of unpurified biological samples with label-free biosensor technology.
Corning’s Epic system is the world’s first high-throughput, label-free screening system. It uses patented optical biosensor technology to enable the study of a broad range of biochemical and cell-based targets. Corning launched the system in 2006 and deployed it at customer sites in North America, Europe and Asia, according to the company.
This latest patent, U.S. Patent No. 7,349,080 entitled “Label-independent Detection of Unpurified Analytes,” adds to Corning’s extensive patent portfolio related to the Epic System and label-free, optical biosensor technology. Previously, Corning acquired exclusive rights to U.S. Patent No. 5,738,825, a fundamental patent related to optical-based biosensors in a microplate format.
“We are committed to enabling our customers to realize the great potential of label-free technology in drug discovery and beyond,” said Ron Verkleeren, Epic business director, Corning Incorporated.
Release Date: May 21, 2008
Source: Corning Incorporated
Filed Under: Drug Discovery